Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 3
1965 1
1966 3
1967 5
1968 6
1969 4
1970 8
1971 3
1972 3
1973 1
1975 3
1976 1
1978 5
1979 3
1980 2
1981 2
1982 6
1983 6
1984 3
1985 2
1986 3
1987 3
1988 1
1989 4
1990 3
1991 2
1992 5
1993 5
1994 5
1995 2
1996 4
1997 5
1998 6
2000 3
2001 4
2002 2
2003 1
2004 3
2005 4
2006 11
2007 15
2008 20
2009 16
2010 11
2011 8
2012 10
2013 5
2014 18
2015 14
2016 21
2017 29
2018 19
2019 30
2020 38
2021 35
2022 57
2023 59
2024 41
2025 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

573 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Li BT, et al. Among authors: nagasaka m. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. N Engl J Med. 2022. PMID: 34534430 Free PMC article. Clinical Trial.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: nagasaka m. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Free PMC article. Clinical Trial.
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer.
Grant C, Nagasaka M. Grant C, et al. Among authors: nagasaka m. Cancer Treat Rev. 2024 May;126:102724. doi: 10.1016/j.ctrv.2024.102724. Epub 2024 Mar 27. Cancer Treat Rev. 2024. PMID: 38636443 Free article. Review.
Neoadjuvant therapy in non-small cell lung cancer.
Grant C, Hagopian G, Nagasaka M. Grant C, et al. Among authors: nagasaka m. Crit Rev Oncol Hematol. 2023 Oct;190:104080. doi: 10.1016/j.critrevonc.2023.104080. Epub 2023 Aug 1. Crit Rev Oncol Hematol. 2023. PMID: 37532102 Free article. Review.
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Schram AM, et al. Among authors: nagasaka m. N Engl J Med. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008. N Engl J Med. 2025. PMID: 39908431 Free PMC article. Clinical Trial.
Preface.
Nagasaka M, Chen G. Nagasaka M, et al. Cancer Metastasis Rev. 2022 Jun;41(2):245-246. doi: 10.1007/s10555-022-10044-4. Cancer Metastasis Rev. 2022. PMID: 35725839 No abstract available.
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA. Smit EF, et al. Among authors: nagasaka m. Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. Lancet Oncol. 2024. PMID: 38547891 Clinical Trial.
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, Sanborn RE, Cho EK, Lee KH, Minchom A, Lee JS, Han JY, Nagasaka M, Sabari JK, Ou SI, Lorenzini P, Bauml JM, Curtin JC, Roshak A, Gao G, Xie J, Thayu M, Knoblauch RE, Park K. Cho BC, et al. Among authors: nagasaka m. Nat Med. 2023 Oct;29(10):2577-2585. doi: 10.1038/s41591-023-02554-7. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37710001 Free PMC article. Clinical Trial.
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
Pérol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. Pérol M, et al. Among authors: nagasaka m. J Clin Oncol. 2025 Jun;43(16):1920-1929. doi: 10.1200/JCO-25-00275. Epub 2025 Apr 3. J Clin Oncol. 2025. PMID: 40179330 Free PMC article. Clinical Trial.
573 results